OS Therapies
OSTX | AMEX
$0.68
-$0.06 (-8.72%)
At close: Nov 16, 2026, 4:00 PM ET
$0.68
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:55 PM ET
OS Therapies Company Profile
Company profile explainedCompany Profile
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
Key Executives
| Name | Position |
|---|---|
| Paul A. Romness | Founder, Chairman, President & Chief Executive Officer |
| Christopher Acevedo | Chief Financial Officer |
| Francis Knuettel | Chief Financial Officer |
| Gerald E. Commissiong | Chief Business Officer |
| Jack Doll | Chief of Staff |
| Kerry Clem | Chief Commercial Officer |
| Robert G. Petit | Chief Medical Officer & Chief Scientific Officer |
OS Therapies
| Country | United States |
| IPO Date | Aug 1, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Paul A. Romness |
Contact Details
115 Pullman Crossing Road Grasonville,
Maryland 21638 United States
Stock Details
| Ticker Symbol | OSTX |
| Exchange | AMEX |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001795091 |
| CUSIP Number | 68764Y207 |
| ISIN Number | US68764Y2072 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove OSTX